{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:52:39Z","timestamp":1788720759707,"version":"build-2803163510"},"reference-count":54,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006020","name":"Center for Translational Molecular Medicine","doi-asserted-by":"publisher","award":["project no. 03O-301"],"award-info":[{"award-number":["project no. 03O-301"]}],"id":[{"id":"10.13039\/501100006020","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006020","name":"Center for Translational Molecular Medicine","doi-asserted-by":"publisher","award":["project no. 09P-106"],"award-info":[{"award-number":["project no. 09P-106"]}],"id":[{"id":"10.13039\/501100006020","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vrienden UMC Utrecht","award":["n.a.p."],"award-info":[{"award-number":["n.a.p."]}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UU 2015-7891"],"award-info":[{"award-number":["UU 2015-7891"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,10,21]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In breast cancer, local tumour control is thought to be optimised by administering higher local levels of cytotoxic chemotherapy, in particular doxorubicin. However, systemic administration of higher dosages of doxorubicin is hampered by its toxic side effects. In this study, we aim to increase doxorubicin deposition in the primary breast tumour without changing systemic doxorubicin concentration and thus without interfering with systemic efficacy and toxicity. This is to be achieved by combining Lyso-Thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox, Celsion Corporation, Lawrenceville, NJ, USA) with mild local hyperthermia, induced by Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU). When heated above 39.5\u00b0C, LTLD releases a high concentration of doxorubicin intravascularly within seconds. In the absence of hyperthermia, LTLD leads to a similar biodistribution and antitumour efficacy compared with conventional doxorubicin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This is a single-arm phase I study in 12 chemotherapy-na\u00efve patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      stage IV HER2-negative breast cancer. Previous endocrine treatment is allowed. Study treatment consists of up to six cycles of LTLD at 21-day intervals, administered during MR-HIFU-induced hyperthermia to the primary tumour. We will aim for 60\u2009min of hyperthermia at 40\u00b0C\u201342\u00b0C using a dedicated MR-HIFU breast system (Profound Medical, Mississauga, Canada). Afterwards, intravenous cyclophosphamide will be administered. Primary endpoints are safety, tolerability and feasibility. The secondary endpoint is efficacy, assessed by radiological response.\n                    <\/jats:p>\n                    <jats:p>\n                      This approach could lead to optimal loco-regional control with less extensive or even no surgery, in\n                      <jats:italic>de novo<\/jats:italic>\n                      stage IV patients and in stage II\/III patients allocated to receive neoadjuvant chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has obtained ethical approval by the Medical Research Ethics Committee Utrecht (Protocol NL67422.041.18, METC number 18-702). Informed consent will be obtained from all patients before study participation. Results will be published in an academic peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT03749850\">NCT03749850<\/jats:ext-link>\n                      , EudraCT 2015-005582-23.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040162","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T15:35:55Z","timestamp":1606404955000},"page":"e040162","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in\n                    <i>de novo<\/i>\n                    stage IV breast cancer patients: study protocol of the i-GO study"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03749850","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-4215","authenticated-orcid":false,"given":"Josanne S","family":"de Maar","sequence":"first","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt B M","family":"Suelmann","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon N G J A","family":"Braat","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P J","family":"van Diest","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H H B","family":"Vaessen","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen J","family":"Witkamp","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S C","family":"Linn","sequence":"additional","affiliation":[{"name":"Departments of Molecular Pathology and Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrit T W","family":"Moonen","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsken","family":"van der Wall","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Deckers","sequence":"additional","affiliation":[{"name":"Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"2025121511461431000_10.11.e040162.1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025121511461431000_10.11.e040162.2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk005"},{"key":"2025121511461431000_10.11.e040162.3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000227402","article-title":"Comparative chemosensitivity profiles in three human breast cancer cell lines with the ATP-cell viability assay","volume":"51","author":"Koechli","year":"1994","journal-title":"Oncology"},{"key":"2025121511461431000_10.11.e040162.4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101512","article-title":"Tumor drug distribution after local drug delivery by hyperthermia, in vivo","volume":"11","author":"Besse","year":"2019","journal-title":"Cancers"},{"key":"2025121511461431000_10.11.e040162.5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<245::AID-CNCR7>3.0.CO;2-P"},{"key":"2025121511461431000_10.11.e040162.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3779"},{"key":"2025121511461431000_10.11.e040162.7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.16.1205"},{"key":"2025121511461431000_10.11.e040162.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.063"},{"key":"2025121511461431000_10.11.e040162.9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semradonc.2015.08.004","article-title":"Surgical management of de novo stage IV breast cancer","volume":"26","author":"Khan","year":"2016","journal-title":"Semin Radiat Oncol"},{"key":"2025121511461431000_10.11.e040162.10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3892\/mco.2016.778","article-title":"Surgical treatment of the primary tumour improves the overall survival in patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"4","author":"Headon","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"2025121511461431000_10.11.e040162.11","doi-asserted-by":"crossref","unstructured":"Soran A , Ozmen V , Ozbas S , et al . The importance of primary surgery in patients with de novo stage IV breast cancer; finalizing the protocol MF07-01 randomized clinical trial. Poster P1-20-01 at San Antonio Breast Cancer Symposium 2019 2019.","DOI":"10.1158\/1538-7445.SABCS19-P1-20-01"},{"key":"2025121511461431000_10.11.e040162.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00135-7"},{"key":"2025121511461431000_10.11.e040162.13","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.21037\/tcr.2020.01.60","article-title":"Effect of local surgery on outcomes of stage IV breast cancer","volume":"9","author":"Tsukioki","year":"2020","journal-title":"Transl Cancer Res"},{"key":"2025121511461431000_10.11.e040162.14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA2","article-title":"A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)","volume":"38","author":"Khan","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121511461431000_10.11.e040162.15","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1016\/j.biomaterials.2012.03.018","article-title":"Pharmacokinetics & tissue distribution of temperature-sensitive liposomal doxorubicin in tumor-bearing mice triggered with mild hyperthermia","volume":"33","author":"Al-Jamal","year":"2012","journal-title":"Biomaterials"},{"key":"2025121511461431000_10.11.e040162.16","first-page":"1197","article-title":"A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model","volume":"60","author":"Needham","year":"2000","journal-title":"Cancer Res"},{"key":"2025121511461431000_10.11.e040162.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(01)00233-2"},{"key":"2025121511461431000_10.11.e040162.18","first-page":"6950","article-title":"Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release","volume":"60","author":"Kong","year":"2000","journal-title":"Cancer Res"},{"key":"2025121511461431000_10.11.e040162.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.12.011"},{"key":"2025121511461431000_10.11.e040162.20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3109\/02656736.2012.736670","article-title":"Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia","volume":"28","author":"Staruch","year":"2012","journal-title":"Int J Hyperthermia"},{"key":"2025121511461431000_10.11.e040162.21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/RLI.0b013e3182806940","article-title":"Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin","volume":"48","author":"de Smet","year":"2013","journal-title":"Invest Radiol"},{"key":"2025121511461431000_10.11.e040162.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.03.011"},{"key":"2025121511461431000_10.11.e040162.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.09.005"},{"key":"2025121511461431000_10.11.e040162.24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju082","article-title":"Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results","volume":"106","author":"Hurwitz","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025121511461431000_10.11.e040162.25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.7150\/jca.13906","article-title":"Clinical application of high-intensity focused ultrasound in cancer therapy","volume":"7","author":"Hsiao","year":"2016","journal-title":"J Cancer"},{"key":"2025121511461431000_10.11.e040162.26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ijrobp.2016.03.019","article-title":"Magnetic resonance-guided high-intensity focused ultrasound hyperthermia for recurrent rectal cancer: Mr thermometry evaluation and preclinical validation","volume":"95","author":"Chu","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121511461431000_10.11.e040162.27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/02656736.2018.1550815","article-title":"Longer heating duration increases localized doxorubicin deposition and therapeutic index in VX2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin","volume":"36","author":"Bing","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"2025121511461431000_10.11.e040162.28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/02656736.2019.1685684","article-title":"Feasibility and safety assessment of magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-mediated mild hyperthermia in pelvic targets evaluated using an in vivo porcine model","volume":"36","author":"Zhu","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"2025121511461431000_10.11.e040162.29","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.21272"},{"key":"2025121511461431000_10.11.e040162.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-012-0526-6"},{"key":"2025121511461431000_10.11.e040162.31","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1088\/0031-9155\/60\/14\/5527","article-title":"Performance analysis of a dedicated breast MR-HIFU system for tumor ablation in breast cancer patients","volume":"60","author":"Deckers","year":"2015","journal-title":"Phys Med Biol"},{"key":"2025121511461431000_10.11.e040162.32","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00330-016-4222-9","article-title":"First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation","volume":"26","author":"Merckel","year":"2016","journal-title":"Eur Radiol"},{"key":"2025121511461431000_10.11.e040162.33","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2014.936049"},{"key":"2025121511461431000_10.11.e040162.34","doi-asserted-by":"publisher","DOI":"10.2217\/fon.11.73"},{"key":"2025121511461431000_10.11.e040162.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2433"},{"key":"2025121511461431000_10.11.e040162.36","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1470-2045(18)30332-2","article-title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025121511461431000_10.11.e040162.37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1148\/radiol.2018181445","article-title":"Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: results from a phase I trial","volume":"291","author":"Gray","year":"2019","journal-title":"Radiology"},{"key":"2025121511461431000_10.11.e040162.38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40349-016-0063-x","article-title":"Procedural sedation and analgesia for respiratory-gated MR-HIFU in the liver: a feasibility study","volume":"4","author":"van Breugel","year":"2016","journal-title":"J Ther Ultrasound"},{"key":"2025121511461431000_10.11.e040162.39","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910340606"},{"key":"2025121511461431000_10.11.e040162.40","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910340313"},{"key":"2025121511461431000_10.11.e040162.41","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the functional assessment of cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"key":"2025121511461431000_10.11.e040162.42","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","article-title":"Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing","volume":"8 Suppl 1","author":"Abetz","year":"2005","journal-title":"Value Health"},{"key":"2025121511461431000_10.11.e040162.43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11136-015-1062-z","article-title":"Reliability and validity of the cancer therapy satisfaction questionnaire in lung cancer","volume":"25","author":"Cheung","year":"2016","journal-title":"Qual Life Res"},{"key":"2025121511461431000_10.11.e040162.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025121511461431000_10.11.e040162.45","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50 Suppl 1","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"2025121511461431000_10.11.e040162.46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh393"},{"key":"2025121511461431000_10.11.e040162.47","unstructured":"Celsion Corporation . ThermoDox\u00ae, Lyso-Thermosensitive Liposomal Doxorubicin (LTLD), Investigator\u2019s Brochure; 2019."},{"key":"2025121511461431000_10.11.e040162.48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jvir.2011.10.018","article-title":"Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies","volume":"23","author":"Wood","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"2025121511461431000_10.11.e040162.49","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"key":"2025121511461431000_10.11.e040162.50","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200303000-00008"},{"key":"2025121511461431000_10.11.e040162.51","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746120-00005"},{"key":"2025121511461431000_10.11.e040162.52","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685716"},{"key":"2025121511461431000_10.11.e040162.53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00280-002-0542-3","article-title":"A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)","volume":"51","author":"Callies","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025121511461431000_10.11.e040162.54","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0900-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:46:25Z","timestamp":1765827985000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,26]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-040162"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040162","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}